Loading...

Afsaneh Barzi, MD

Title(s)Associate Professor Of Clinical Medicine
Phone+1 323 865 3829
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    National Cancer Institute2013Travel Award for Markers in Cancer
    Southwest Oncology Group2011Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Barzi earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master’s in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. She recently completed a fellowship in hematology and oncology at the Cleveland Clinic’s Taussig Cancer Center.

    Her research interests are the development of new cancer therapies as well as healthcare economics and metrics of healthcare quality for improving patient care. Dr. Barzi has proposed a phase II study to investigate the overall survival benefit of adding lapatinib to docetaxel in a second line setting in patients with trastuzumab-resistant, HER2-positive gastric cancer.

    “Delivery of personalized treatment to gastric cancer patients has lagged behind other diseases,” Barzi says. “My goal is to establish a second-line treatment for these patients that are HER2-positive and to better understand the mechanisms of resistance to HER2-targeted therapy, paving the way for new therapies that can overcome that resistance.”

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 Aug 09. PMID: 31398279.
      View in: PubMed
    2. Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. Arch Osteoporos. 2019 Jul 28; 14(1):83. PMID: 31352608.
      View in: PubMed
    3. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Jun 28. PMID: 31262657.
      View in: PubMed
    4. Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J. Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma. Cancer Control. 2019 Jan-Dec; 26(1):1073274819847642. PMID: 31056940.
      View in: PubMed
    5. Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. 2019 May 15; 144(10):2567-2577. PMID: 30411783.
      View in: PubMed
    6. Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer. 2019 Jan; 107:100-114. PMID: 30554073.
      View in: PubMed
    7. Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan; 107:115-123. PMID: 30557792.
      View in: PubMed
    8. Xu Y, Hay JW, Barzi A. Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Eff Resour Alloc. 2018; 16:30. PMID: 30459532.
      View in: PubMed
    9. Tambe B, Wang CV, Noren E, Duldulao MP, Barzi A, Lee SW. Tertiary Care Multidisciplinary Teams Associated with Improved Survival in Rectal Cancer Patients: A Comparative Study. Am Surg. 2018 Oct 01; 84(10):1645-1649. PMID: 30747687.
      View in: PubMed
    10. Cho SK, Hay JW, Barzi A. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clin Colorectal Cancer. 2018 12; 17(4):e751-e761. PMID: 30228027.
      View in: PubMed
    11. Veyseh M, Ricker C, Espenschied C, Raymond V, D'Souza A, Barzi A. Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol. 2018; 8:259. PMID: 30050867.
      View in: PubMed
    12. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018 09; 18(5):623-632. PMID: 29925895.
      View in: PubMed
    13. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. PMID: 29679564.
      View in: PubMed
    14. Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018 May; 66:15-22. PMID: 29631196.
      View in: PubMed
    15. Kim S, Barzi A, Rajdev L. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. Semin Oncol. 2018 06; 45(3):133-150. PMID: 30262395.
      View in: PubMed
    16. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. PMID: 29606345.
      View in: PubMed
    17. Barzi A, Yang D, Mostofizadeh S, Lenz HJ. Trends in colorectal cancer mortality in hispanics: a SEER analysis. Oncotarget. 2017 Dec 12; 8(65):108771-108777. PMID: 29312566.
      View in: PubMed
    18. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 11; 86:197-206. PMID: 28992563.
      View in: PubMed
    19. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017 Nov 15; 123(22):4506-4514. PMID: 28708932.
      View in: PubMed
    20. Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer. 2017 Oct 01; 123(19):3732-3743. PMID: 28640387.
      View in: PubMed
    21. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. PMID: 28369940.
      View in: PubMed
    22. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017 05 01; 28(5):1015-1022. PMID: 28453695.
      View in: PubMed
    23. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 07; 35(7):459.e15-459.e24. PMID: 28284890.
      View in: PubMed
    24. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 05 06; 67(3):177-193. PMID: 28248415.
      View in: PubMed
    25. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. PMID: 28117881.
      View in: PubMed
    26. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. PMID: 28096270.
      View in: PubMed
    27. Lee E, Liu L, Zhang J, Stern MC, Barzi A, Hwang A, Kim AE, Hamilton AS, Wu AH, Deapen D. Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese. Cancer Epidemiol Biomarkers Prev. 2017 04; 26(4):587-596. PMID: 27908922.
      View in: PubMed
    28. Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J. 2018 01; 18(1):43-48. PMID: 27698403.
      View in: PubMed
    29. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. PMID: 27449091.
      View in: PubMed
    30. Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clin Colorectal Cancer. 2016 12; 15(4):e221-e227. PMID: 27553907.
      View in: PubMed
    31. Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. PMID: 26666409.
      View in: PubMed
    32. Grubman J, Barzi A. Lost in Translation: The Patient-Physician Relationship in the Molecular Era. J Palliat Med. 2015 Nov; 18(11):987-8. PMID: 26418297.
      View in: PubMed
    33. Grubman J, Barzi A. We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. J Adolesc Young Adult Oncol. 2015 Sep; 4(3):105-7. PMID: 26421219.
      View in: PubMed
    34. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. PMID: 26227487.
      View in: PubMed
    35. Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. Ann Oncol. 2015 Aug; 26(8):1728-33. PMID: 25957329.
      View in: PubMed
    36. Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). PMID: 25794514.
      View in: PubMed
    37. Barzi A, Lenz HJ. Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3):183-4; 186. PMID: 25783978.
      View in: PubMed
    38. Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. PMID: 25203738.
      View in: PubMed
    39. Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015 Feb; 26(2):332-9. PMID: 25411415.
      View in: PubMed
    40. Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. PMID: 25203737.
      View in: PubMed
    41. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. PMID: 25091263.
      View in: PubMed
    42. Barzi A, Thara E. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opin Biol Ther. 2014 Sep; 14(9):1319-32. PMID: 24881691.
      View in: PubMed
    43. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. PMID: 24188686.
      View in: PubMed
    44. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: Estrogen pathway in colorectal cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5842-8. PMID: 23965904.
      View in: PubMed
    45. Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. PMID: 23918832.
      View in: PubMed
    46. Barzi A, Lenz HJ. Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. PMID: 22860627.
      View in: PubMed
    47. Sadeghi S, Barzi A, Kattan MW, Meropol NJ. Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. PMID: 21372042.
      View in: PubMed
    48. Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med. 2010 Jan; 77(1):37-44. PMID: 20048028.
      View in: PubMed
    49. Sadeghi S, Barzi A, Sadeghi N, King B. A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. PMID: 16140572.
      View in: PubMed
    50. Sadeghi S, Barzi A, Smith JW. Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. PMID: 16160263.
      View in: PubMed
    51. Barzi A, Sadeghi S, King BR. Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. PMID: 15458058.
      View in: PubMed
    52. Brutti A, Liberati AM, Biscottini B, Fatati G, Sini S, Barzi AM, Grignani F. Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. Tumori. 1979 Jun 30; 65(3):339-44. PMID: 462584.
      View in: PubMed
    Afsaneh's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (245) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (26) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑